SBFM — Sunshine Biopharma Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1402328 ·
Last close
$0.42
Market Cap
$6.73M
52W High
$2.32
52W Low
$0.28
ADV30
26,746,712
Next earnings
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 8,088,765 2,180,990 -1,395,597 -1,243,869 27,930,375 6,913,013 6,413,781
Dec 2025 8,577,141 3,028,845 -1,658,223 -2,140,927 30,079,167 9,123,308 7,040,707
Sep 2025 9,417,179 3,073,540 -531,963 -883,820 31,487,379 9,306,438 7,288,023
Jun 2025 9,410,230 3,422,866 -992,846 -1,770,834 31,965,250 10,305,320 6,280,446

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,331,073
Investing CF
$-836,306
Financing CF
$4,748,408
CapEx
$-836,306
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-1.96
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-75,015,126
Inventory
$13,472,025
Receivables
$3,459,864
ST Investments
EBIT TTM
$-5,953,743
Pretax Income TTM
$-5,953,743
Interest Exp TTM
$0
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$35,493,316
EBITDA
$-4,234,493
Free Cash Flow
$-4,710,076
Enterprise Value
$-3,745,811
Total Cash
$6,913,013
Total Debt
$744,840
Shares Out
16,165,945
Trailing EPS
$-1.25
Book Value
$4.69
ROE
-27.3%
ROA
-10.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 36,305,891 -4,478,782 -5,975,352 30,079,167 7,040,707 -5,331,073
Dec 2024 34,874,283 -5,812,121 -5,134,116 30,560,392 7,059,638 -12,524,779
Dec 2023 24,092,787 -4,785,299 -4,506,044 27,346,961 6,139,600 -8,775,111
Dec 2022 4,345,603 -8,674,031 -26,744,440 29,243,848 7,616,278 -5,248,358

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$199.80

Peers — same industry

TickerNameMarket CapLastDaily %
SILO Silo Pharma, Inc. $6.69M $0.41
PCSA Processa Pharmaceuticals, Inc. $6.88M $2.50
ASBP Aspire Biopharma Holdings, Inc. $6.57M $5.07
SYBX SYNLOGIC, INC. $7.02M $0.60
XBIO Xenetic Biosciences, Inc. $7.02M $3.07

News headlines (Yahoo Finance, 1h cache)

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
2026-05-21 11:00 · Yahoo
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
2026-05-19 16:05 · Yahoo
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
2026-05-18 16:15 · Yahoo
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
2026-04-06 12:30 · Yahoo
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
2025-10-28 18:10 · Yahoo
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
2025-10-28 11:45 · Yahoo
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
2025-10-20 11:45 · Yahoo
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
2025-10-16 11:45 · Yahoo
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
2025-10-14 14:45 · Yahoo
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
2025-10-14 12:50 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.